-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3786 Satisfaction and Experiences with Talquetamab: Results from Qualitative Patient and Physician Research

Program: Oral and Poster Abstracts
Session: 907. Outcomes Research: Plasma Cell Disorders: Poster II
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Adverse Events
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Beth M. Faiman, PhD, CNP1, Cesar Rodriguez, MD2*, Smith Giri, MD, MHS3*, Christine Brittle, PhD4*, Jay R. Hydren, PhD5, Karla Mariana Castro Bórquez, MD5*, Maria Gambill, BA5*, Ana M. Sahagun Sanchez Aldana, MS5*, Jennifer M. Ahlstrom, BA5*, Hoa H. Le, PhD6*, Saurabh N. Patel, MD6*, Kathleen S Gray6*, Xinke Zhang, PhD6* and Rafael Fonseca, MD7

1Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Division of Hematology-Oncology, Department of Internal Medicine, Mount Sinai, New York, NY
3Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
4CorEvitas, Waltham, MA
5HealthTree Foundation, Lehi, UT
6Johnson & Johnson Innovative Medicine, Horsham, PA
7Division of Hematology, Mayo Clinic, Paradise Valley, AZ

Introduction

Talquetamab (Tal) is a bispecific antibody therapy approved for patients with relapsed/refractory multiple myeloma (MM), targeting both GPRC5D x CD3 receptors. Clinical studies demonstrate that Tal creates deep and durable responses, but less is known about the patient experience. This study aimed to explore the experiences of patients from the patient and physician perspectives to help understand what to expect with this first-in-class novel therapy.

Methods

This qualitative study consisted of two components. First, patients with documented use of Tal were identified and recruited through the HealthTree Cure Hub. Individual patients then took part in 2-hour, semi-structured virtual interviews. Patients were asked to discuss their experiences 1-2 months prior to starting Tal and 4-5 months after beginning therapy. Patients discussed GPRC5D-related symptoms (including oral, skin-related, and nail-related symptoms), overall impact, and satisfaction. Participants were US adults diagnosed with MM who took Tal for at least 4 months, either in a clinical trial or commercial setting. Interviews were conducted February-April 2024. Second, patients and physicians gathered in a facilitated roundtable discussion to review findings and generate ideas for symptom management. The roundtable lasted 2.5 hours and took place in Chicago, IL in May 2024.

Results

Eight men and 4 women (n=12) aged 52-79 years participated in the interviews. Interviewed participants were mostly white (84%) and college-educated (84%). Seven (58%) received Tal in a clinical trial, and 9 were still receiving Tal. Roundtable participants included 3 patients (2 male, 1 female; all white and college educated), and 3 physicians with Tal experience.

In the interviews, patients reported high overall satisfaction, with most (75%) rating their satisfaction an 8 or higher on a 10-point scale. Satisfaction was largely driven by the effectiveness of therapy, with all reporting clinical improvements in their MM disease. Patients reported improvements in their energy/strength and decreased fatigue. They also reported increased physical activities and ability to work, volunteer, or engage in hobbies. Physicians affirmed these findings as consistent with their observations and noted they are also very satisfied with Tal.

Oral symptoms such as distorted taste/loss of taste and dry mouth were common with varying severity. Although all interviewees (n=12) reported taste symptoms (typically starting within the first month of therapy), five said their symptoms fully improved (3 after 1 year on treatment, and 2 after stopping treatment), and 4 experienced partial recovery. Ten lost weight, but most (92%) maintained adequate nutrition. Patients and physicians suggested coping strategies including diet modifications, use of strong flavors (e.g., spices, cinnamon), monitoring weight, prioritizing adequate calories, using mouthwashes/lozenges, drinking water while eating, taking small bites, and consuming foods that are easier to swallow. They also noted that it is important to educate patients on expected symptoms before starting the treatment.

Skin- and nail-related symptoms were also common but less impactful on quality of life. All patients (n=12) experienced skin- and nail-related symptoms, but most considered these symptoms mild. Skin-related symptoms such as dry skin and skin exfoliation occurred once and typically lasted 1-2 months. Nail symptoms were primarily cosmetic, and the duration varied. Suggested management strategies include skin moisturizers, nail thickeners/hardeners, keeping nails short, and wearing protective gloves. Physicians noted it’s helpful to reassure patients that nail loss is not harmful.

Overall, GPRC5D-related symptoms were not treatment-limiting, and no patients had to miss a dose due to these symptoms. Patients perceived these symptoms as bearable but noted the treatment was effective at controlling the disease.

Conclusions

This study described patient experiences and reflected how patients perceive the benefit/risk profile of talquetamab. Symptoms were perceived as bearable and high satisfaction scores were driven by strong clinical effectiveness. Patients and physicians agreed that real-world feedback from patients, practical tips, and management strategies are vitally important for patients and physicians using this novel therapy.

Disclosures: Rodriguez: AbbVie: Consultancy; BMS: Consultancy; Johnson and Johnson: Consultancy; Janssen: Consultancy; Takeda: Consultancy; Sanofi: Consultancy; Amgen: Consultancy; Karyopharm Therapeutics: Consultancy. Giri: CareVive: Honoraria, Research Funding; PackHealth: Research Funding; Sanofi: Honoraria, Research Funding; Janssen: Honoraria, Research Funding. Brittle: Johnson & Johnson Innovative Medicince: Consultancy. Hydren: GlaxoSmithKline: Research Funding; Regeneron: Research Funding; Sanofi: Research Funding; BioLinRx: Research Funding; Pfizer: Research Funding; Johnson and Johnson Innovative Medicine: Research Funding; Takeda Oncology: Research Funding; Adaptive Biotechnologies: Research Funding. Ahlstrom: Pfizer: Other: Patient advocacy; BMS: Other: Patient advocacy; Janssen: Other: Patient advocacy; Takeda Oncology: Other: Patient advocacy; Sanofi: Other: Patient advocacy. Le: Johnson & Johnson Innovative Medicine: Current Employment, Current equity holder in publicly-traded company. Patel: Johnson & Johnson Innovative Medicine: Current Employment, Current equity holder in publicly-traded company. Gray: Janssen Research & Development, LLC: Current Employment, Current equity holder in publicly-traded company. Zhang: Johnson & Johnson Innovative Medicine: Current Employment, Current equity holder in publicly-traded company. Fonseca: Celgene, Bristol Myers Squibb, Bayer, Amgen, Janssen, Kite, a Gilead company, Merck Sharp & Dohme, Juno Therapeutics, Takeda, AbbVie, Aduro Biotech, Sanofi, OncoTracker: Honoraria; AbbVie, Adaptive, Amgen, Apple, Bayer, BMS/Celgene, Gilead, GSK, Janssen, Kite, Karyopharm, Merck Sharp & Dohme, Juno Therapeutics, Takeda, Arduro Biotech, Oncotracker, Oncopeptides, Pharmacyclics, Pfizer, RA Capital, Regeneron, Sanofi: Consultancy; Patent for FISH in MM - ~$2000/year: Patents & Royalties: Patent for FISH in MM - ~$2000/year; Antengene: Membership on an entity's Board of Directors or advisory committees.

*signifies non-member of ASH